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a,b Saudi ArabiaBackground: Atrial fibrillation (AF) is the most common chronic rhythm disorder. Patients with AF are at an
increased risk of ischemic stroke. Therefore, optimal anticoagulation is essential to reduce the risk of stroke. The aim of
this study was to assess the level of anticoagulation control achieved in patients with nonvalvular AF receiving medical
care in a tertiary care hospital.
Methods: This was a retrospective cohort study in ambulatory care clinics at tertiary care hospital in Saudi Arabia.
We included 110 nonvalvular AF patients treated with warfarin for at least 3 months at King Abdulaziz Medical
City, Riyadh, Saudi Arabia, betweenMay 1, 2012, and July 31, 2012. Thereafter, international normalized ratio results
were collected for 1 year. Anticoagulation control was assessed by calculating time within therapeutic range (TTR)
as per the Rosendaal method.
Results: The mean age was 64.9  16.5 years; 60.9% were female. The mean TTR was 59%. Almost one third of the
patients (32.7%) had poor anticoagulation control; TTR of <50%. Poor anticoagulation control was significantly
associated with higher CHADS2 (congestive heart failure, hypertension, age, diabetes, stroke) score (p = 0.043).
TTR was not significantly different between men and women. Similarly, TTR was not associated with age or
duration of anticoagulation. There was no adequate information to assess the effect of other factors such as diet,
compliance, and level of education on anticoagulation. Thirty-one patients (28.2%) had a history of prior stroke.
The overall quality of anticoagulation was not significantly different between patients with and without stroke,
(TTR was 56.3% and 60.1%, respectively; p = 0.46).
Conclusion: Quality of anticoagulation in patients with AF receiving medical care in a tertiary care hospital was
suboptimal, with nearly 40% of the time spent outside the therapeutic range. Methods to improve anticoagulation
control among patients with AF should be implemented.
 2016 Production and Hosting by Elsevier B.V. on behalf of King Saud University. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Abbreviations
AF atrial fibrillation
CHADS2 congestive heart failure, hypertension, age,
diabetes, stroke
INR international normalized ratio
TTR time in therapeutic range
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Atrial fibrillation (AF) is the most common car-diac rhythm disorder. It is associated with a
4–5-fold increased risk for ischemic stroke [1]. The
use of oral anticoagulants such as warfarin has
been shown in the clinical trials to reduce the risk
of ischemic stroke [2,3]. Thus, warfarin therapy is
widely used in patients with AF with high
CHADS2 (congestive heart failure, hypertension,
age, diabetes, stroke) score and is recommended
by various medical societies including the Ameri-
can College of Chest Physicians, Glenview, IL,
USA [4–6]. Nevertheless, in order to achieve max-
imal protection against stroke and to minimize
bleeding complications, warfarin therapy must
be tightly controlled and maintained within a nar-
row therapeutic range of international normalized
ratio (INR) values between 2 and 3. This task is not
easy to achieve as INR levels are known to be
influenced by several factors including patient
age, concurrent medications, genetic makeup,
herb consumption, and diet [7,8]. As a result, oral
anticoagulant therapy requires regular monitor-
ing, which can be inconvenient for patients and
healthcare providers. The time spent within the
therapeutic range (TTR) is the recommend tool
used to assess the quality of the anticoagulation
control and has a paramount effect on patient out-
come such as stroke events and mortality [5,9].
The literature acknowledges the superior out-
comes of anticoagulation clinics over routine med-
ical care in terms of anticoagulation control in theTable 1. Baseline characteristics.
Variable All patients n = 110
Age (y) 65.9 ± 16.5
Female 67 (60.9)
Height (cm) 155.6 ± 21.1
Weight (kg) 76.9 ± 16.6
BMI (kg/m2) 32.8 ± 18.8
CHADS2 2.8 + 1.1
CHADS2 62 61 (55.5)
CHADS2 2.1–4 36 (33.6)
CHADS2 >4 12 (10.9)
Prior stroke 31 (28.2)
TTR Rosendaal 59.0 ± 24.2
TTR (average%) 55.6 ± 22.3
Follow-up duration 284.4 ± 73.1
INR 2–3 491 (55.6)
INR <2 246 (27.9)
INR >3 146 (16.5)
Data are presented as n (%) or mean ± standard deviation.
BMI = body mass index; CHADS2 = congestive heart failure, hyper-
tension, age, diabetes, stroke; INR = international normalized ratio;
TTR = time in therapeutic range.USA [10]. In this study we describe the quality of
anticoagulation control achieved in patients with
AF receiving medical care within specialized anti-
coagulation clinic operated by clinical pharmacist
in a tertiary care center in Saudi Arabia. The pur-
pose of this study was to assess the quality of anti-
coagulation control (expressed as TTR) and to
explore specific patient related factors that may
have significant impact on the level of
anticoagulation.Material and methods
This was a retrospective cohort study conducted
at King Abdulaziz Medical City (KAMC), Riyadh,
Saudi Arabia from May 1, 2012 to April 30, 2013.
The hospital is a tertiary care center with well-
developed infrastructure including the use of
electronic medical records. All patients had full
medical coverage by the National Guard Health
Affairs with pharmacy benefits for prescription
medication. A computerized anticoagulation clinic
database was used to identify all patients with a
diagnosis of AF who were treated with warfarin
for at least 3 months prior to the study period.
Patients were excluded if they fulfilled any of the
following criteria: (1) were younger than 18 years;
(2) had an active malignancy; (3) had indication
for anticoagulation other than AF; (4) had valvular
heart disease; and (5) had fewer than five INR
determinations during the study period. All
records retrieved from the database were audited
manually by a researcher (S.M.A) for concordance
with the above-mentioned criteria. A total of 110
patients met the study inclusion criteria and were
included in the analysis. The patients were man-
aged by a group of clinical pharmacists during
the study period. A computerized database pro-
vided demographics (e.g., age, sex, height, and
weight), medical diagnoses, and CHADS2 score.
In addition, the number and value of INR deter-
minations for each patient were collected for up
to 1 year after the enrolment period. Anticoagula-
tion control was assessed by measurement of time
spent within the therapeutic range TTR (i.e., time
in which patient INR values were between 2 and
3). The therapeutic range was calculated with an
Excel sheet (Microsoft Corporation, Redmond,
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model, as described by Rosendaal et al. [11]. The
TTR was then classified as follows: (1) TTR level
<50% was considered to represent poor anticoagu-
lation control; (2) TTR level between 50% and 75%
was considered to represent good anticoagulation
control; and a (3) TTR level >75% was considered
to represent excellent anticoagulation control.
This stratification allowed characterization of
patient subsets associated with the different con-
trol levels. All statistical analyses were performed
using SPSS, version 20.0 (SPSS Inc., Chicago, IL,
USA). Potential predictors of poor control were
assessed in univariate models (v2 test for categor-
ical variables and analysis of variance for continu-
ous variables). A p value <0.05 was considered
significant. The study was approved by the local
ethical committee (King Abdullah International
Research Centre, IRB) and carried out in accor-
dance with The Code of Ethics of the World Med-
ical Association (Declaration of Helsinki) for
experiments involving humans.Results
Table 1 summarizes clinical characteristics of
study population. The mean age was
64.9 ± 16.5 years; 60.9% were female. Forty-nine
patients (45.5%) had more than two risk factors
for ischemic stroke (age >75 years, diabetes melli-
tus, hypertension, heart failure, or prior stroke).
None were taking antiarrhythmic medications
known to interfere with INR level including amio-
darone, flecainide, propafenone, sotalol, dofeti-
lide, quinidine, or dronedaron. The mean
duration of anticoagulation was 284.4 ± 73.1 days,
during which 883 INR determinations were per-
formed. The average number of INR determina-
tions per patient was 8 ± 1. The mean TTR was
59.0 ± 24.1%. Of 110 patients, 32.7% had poor anti-
coagulation control (Rosendaal TTR <50%), 40.9%
had good control (TTR 50–75%), and only 26.4%
had excellent anticoagulation control (TTR
>75%). Of 883 INR tests, 55.6% were within,Table 2. Patient characteristics associated with poor anticoagulatio
Variable TTR <50 n = 36 TTR
Age (y) 68.6 ± 15.6 63.8
Female 21 (58.3) 27 (
Follow-up duration 271.4 ± 80.3 288.
CHADS2 3.1 ± 1.2 2.7 ±
BMI (kg/m2) 33.2 ± 26.9 31.1
Prior stroke 12 (33.3) 11 (
Data are presented as n (%) or mean ± standard deviation.
BMI = body mass index; CHADS2 = congestive heart failure, hypertension, a
range.27.9% above and 16.5% below the therapeutic
range. Poor anticoagulation control was not asso-
ciated with age, female sex, or duration of antico-
agulation (Table 2). By contrast, there was
significant trend towards worse anticoagulation
control in patients with higher CHADS2 score
(CHADS2 scores were 3.1 ± 1.2, 2.7 ± 1.0, and
2.5 ± 1.0 in patients with poor, good, and excellent
anticoagulation control, respectively; p = 0.043).
Thirty-one patients (28.2%) had a history of prior
stroke. The overall quality of anticoagulation was
not significantly different between patients with
and without stroke (TTR was 56.3% and 60.1%,
respectively; p = 0.46).Discussion
This study showed that patients with nonvalvu-
lar AF receiving medical care by clinical pharma-
cists within a large tertiary care center had
suboptimal anticoagulation control with a mean
TTR of 59%. Additionally, poor anticoagulation
control was observed in patients with higher
CHADS2 scores. Our results are consistent with
the previous studies that showed better anticoag-
ulation control in dedicated anticoagulation clinic
control (TTR, 63%; 95% confidence interval, 58–
68%) [12,13] compared to routine medical care on
a community-based AF anticoagulation control
(TTR, 51%; 95% confidence interval, 47–55%) [14].
We also showed that most of the time spent out
of the therapeutic range is due to inadequate anti-
coagulation rather that over-anticoagulation.
Different patient characteristics are possible
reasons for discrepant control levels. Poor control
has been reported among populations affected by
comorbidities. In our study, we did not analyze
individual comorbid condition as reason for poor
control. However, we found significant association
between the level of anticoagulation and CHADS2
score. Considering that most patients with high
CHADS2 score have history of stoke, it is extre-
mely important to keep optimal TTR in these
patients. By contrast, patients with stoke may haven control.
50–75 n = 45 TTR >75 n = 29 p
± 16.6 62.1 ± 16.9 0.24
60.0) 19 (65.6) 0.83
7 ± 75.5 294.8 ± 56.7 0.40
1.0 2.5 ± 1.0 0.043⁄
± 7.2 34.8 ± 19.0 0.70
24.4) 8 (27.6) 0.67
ge, diabetes, stroke; SD = standard deviation; TTR = time in therapeutic
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without adequate family support, high quality
anticoagulation may not be easily achieved [15].
Our results were similar to those previously
reported, which showed no age or sex difference
among anticoagulation control groups [16]. It is
perceived that longer anticoagulation duration is
associated with poor control [15]. A possible
explanation for this belief is frequent INR deter-
minations and shorter time between visits in
patients recently enrolled in the anticoagulation
clinic compared to those at longer follow-up.
Our result showed that there is no association
between the quality of anticoagulation and
follow-up duration. Moreover, TTR was not differ-
ent between patients who had fewer than five INR
tests during the study period compared to those
with more frequent testing. A number of studies
have addressed the effect of diet on anticoagula-
tion. Mediterranean diet has been recently shown
to have no significant effect on quality of anticoag-
ulation [17]. Herbal consumption, however, had a
significant effect on anticoagulation [18]. There is
no previous study that has addressed specific diet
in the Middle East or Gulf region. In our study, it
was especially difficult to obtain information about
diet in our study cohort. Level of patient education
may affect the anticoagulation level. A previous
study showed that limited health literacy is associ-
ated with poor anticoagulation control for patients
on warfarin therapy [19]. Lack of medication
understanding may hinder the safe and effective
use of this narrow therapeutic index drug. We
believe that patient education during clinic visits
is an essential part of the management. We found
no adequate information related to this aspect. In
a busy clinic, time assigned for each patient may
hinder patient education. Given the retrospective
approach, it was not possible to assess the time
spent with patients in our study cohort. Instead
we reviewed the administrative data over 3 months
and collected information about the number of
patients in each clinic and the time spent with each
patient during their visit to the anticoagulation
clinic; on average each patient spent 8 minutes
being assessed. This was relatively short and, given
the complexity of the medical care in the current
practice, caregivers may have found it impossible
to spend adequate time for education.
Since optimal anticoagulation control is desir-
able on both medical and economic grounds, ways
to improve control should be sought. If good anti-
coagulation control cannot be achieved within the
current care setting, a validated alternative option
such as handheld patient INR meters may beadvisable [20]. In the Japanese population, intro-
duction of point-of-care testing in outpatient clin-
ics was associated with improvement in time in
therapeutic range in anticoagulant-treated
patients [21]. Despite the above-mentioned
efforts, warfarin may not ultimately provide the
optimal anticoagulation needed. Therefore, its
substitution with newer oral anticoagulant drugs
may eventually be inevitable. Such drugs have
recently proved their efficacy and may be the
anticipated substitute for warfarin [22]. As the
newer anticoagulant drugs are associated with
substantial cost, a careful cost–benefit analysis
should be conducted to determine their feasibility.
Poor anticoagulation is associated with
increased risk of stroke and to a lesser extent
major bleeding [4]. Significant improvement in
time to stroke event has been reported in those
patients with INR control of >70% of time in ther-
apeutic range (2.0–3.0) compared with the non-
warfarin treatment group. In our study, nearly
one third of our patients had a history of prior
stroke. The study follow-up duration was short
(284.4 ± 73.1 days, range 46–361 days), so it is
impossible to obtain adequate data about the
impact of anticoagulation on stroke.
Our study has several limitations. First, we were
unable to acquire data concerning clinical out-
comes such as stroke and bleeding event rates
for our study population. For that reason, we
elected to use anticoagulation control as a surro-
gate indicator for outcome, given the strong asso-
ciation between TTR levels and clinical outcomes
[5,9]. Second, we could not assess scheduled inter-
ruptions of oral anticoagulants (i.e., periprocedu-
ral, hospitalization), which may have resulted in
underestimation of the TTR levels of the study
group; finally, our population had a low burden
of comorbidities (55.5% of the patients has
CHAD2 score of 62), which may limit the study’s
generalizability to other settings.Conclusion
This study provides important information
about quality of anticoagulation control of patients
with AF who receive medical care within a large
tertiary care hospital in Saudi Arabia. Overall,
patients with AF had suboptimal control, with
nearly 40% of the time spent out of the therapeutic
range. Patients with high CHADS2 were more
likely to have poor anticoagulation. These patients
in particular could benefit from methods aimed at
improving control such as using point-of-care INR
FU
LL
 L
EN
G
TH
 A
RT
IC
LE
J Saudi Heart Assoc
2016;28:239–243
ALYOUSIF, ALSAILEEK 243
ANTICOAGULATION CONTROL FOR ATRIAL FIBRILLATIONtest, or shifting to new anticoagulant drugs that do
not require blood level monitoring.
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